Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100
Bruno Nervi(Pontificia Universidad Católica de Chile), John F. DiPersio(Washington University in St. Louis), David Piwnica‐Worms(The University of Texas MD Anderson Cancer Center), Michael P. Rettig, Gary Bridger, Timothy J. Ley(Washington University in St. Louis), Julie L. Prior(Imaging Center), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Pablo Ramírez(Instituto Murciano de Investigación Biosanitaria), Matthew Holt, Julie Ritchey
Cited by 481
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k